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Chapter 10 
Valorizatium chapter 
 
The importance of collaboration: open source data and expertise 
sharing should be a pillar of future research 
The studies included in the present dissertation provided several new 
approaches to the study of pharmacogenetics in depression and they 
valorized the importance of data and expertise sharing as a successful model 
for future research.  
Pharmacogenetics is a research field mostly represented by scientists with a 
non-clinical background, such as bioinformatics and statistical genetics. A 
clinical-oriented point of view is therefore precious in psychiatric 
pharmacogenetics, since the importance of a good knowledge of 
psychopharmacology to guide hypothesis formulation and testing. Chapter 
2 of this dissertation provides an example of this concept: the knowledge of 
the pharmacokinetics of antidepressant drugs was the preliminary step for 
the realization of the study which was born as a spontaneous idea during the 
discussion between me (a clinical scientist) and a professor in statistical 
genetics (Cathryn Lewis). Cytochrome P450 (CYP450) genes show a high 
complexity because of their polymorphic nature and the interpretation of the 
consequences of the different possible allelic combinations is not 
straightforward (https://www.pharmvar.org). The direct collaboration with 
experts in complementary fields allowed the combination of 
psychopharmacology, genetics and biostatistics in the study, which was the 
first to demonstrate that CYP2C19 enzymatic level can be accurately 
estimated using imputed genome-wide data (bioinformatics and genetic 
relevant finding) and that CYP2C19 poor metabolizers do not probably 
need any dose reduction when treated with citalopram or escitalopram 
(clinically relevant finding). This provides an example of complementary 
expertise sharing that should guide future studies in order to avoid the 
compartmentalization of science. Genetics and pharmacogenetics should 
indeed not be the ground of non-clinical scientists only. 
Another key point that should be taken into account in research is the 
possibility of accessing previously collected databases that are often 
available to qualified researchers and can provide very valuable resources 
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for primary analyses or replication. We entered in a scientific era more and 
more often characterized by the sharing of not only results but also raw 
data. The initiatives of the US NIMH Center for Collaborative Genomic 
Studies provide a collection of over 150,000 well characterized patient and 
control samples from a wide-range of mental disorders 
(https://www.nimhgenetics.org). Genomic and clinical data from NIMH 
repositories were included in all the studies of this dissertation for 
replication purpose, for providing complementary evidence or as part of the 
primary analysis, demonstrating that open access data can provide 
exceptional extra-value and the importance of not being focused on only in-
house data (which is also much more expensive and time consuming). 
Under the same spirit, data from my ongoing projects will be included in 
international consortiums, such as the Psychiatric Genetics Consortium 
(PGC). Future research should not ignore the resources already available, 
and at the same time sharing our own data should become a routine 
procedure.   
 
Social and economic considerations 
Depressive disorders are the third cause of disability considering all non-
communicable diseases (Disease and Injury Incidence and Prevalence 
Collaborators, 2016). The economic burden of major depression increased 
from $173.2 billion to $210.5 billion in the period 2005-2010 in the US and 
in Europe it was estimated to be ~92 billion of euro in 2010 (Greenberg et 
al., 2015; Olesen et al., 2012). Treatment-resistant depression (TRD) was 
demonstrated to be a relevant factor in contributing to depression-related 
costs (Mrazek et al., 2014). For this reason, several studies included in the 
present dissertation assessed the genetic factors involved in TRD risk 
(chapters 3, 5, and 6). 
In this scenario, the identification of biomarkers able to predict 
antidepressant response and guide treatment prescription is of undoubted 
value. This dissertation identified genetic markers of antidepressant efficacy 
and side effects at individual gene level and at pathway level. At individual 
gene level, there is encouraging evidence that combinatorial approaches 
including relevant polymorphisms can provide clinically meaningful 
information to guide antidepressant treatment, as showed for CYP2C19 and 
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FKBP5 genes in chapter 2 and chapter 3. Pharmacogenetic tests including 
variants in these genes have preliminary evidence of improving remission 
rates compared to standard care (Stamm et al., 2016; Bradley et al., 2018). 
Combinatorial approaches applied at pathway level (i.e. a set of functionally 
related genes) encompass the exciting opportunity to explain a higher 
proportion of variance in antidepressant response and reflect the final 
functional balance of a biological system relevant to antidepressant action. 
The application of predictive modeling at pathway level was tested in 
chapter 3 and it was one of the first studies of this kind in psychiatric 
pharmacogenetics. Many academic centers are planning or implementing 
start up efforts that aim to integrate genomic information and clinical 
information from electronic health records to optimize treatments using 
predictive modeling (Kalinin et al., 2018; Kannry and Williams, 2013). A 
deep learning approach may represent a game-changing advance compared 
to currently available pharmacogenetic tests that are based on the results of 
candidate gene studies (Fabbri et al., 2018).  
 
Starting point for future research 
The studies included in this dissertation were the starting point for planning 
further projects that are now in the implementation phase. Indeed, the study 
of treatment-resistant depression (TRD) and the idea of expanding genomic 
coverage to rare exomic variants were considered particularly promising 
since the paucity of previously published results and the points discussed in 
the previous section. The studies described in chapters 3, 4, 5 and 6 express 
the innovativeness and relevance of these concepts for improving the 
potential impact of pharmacogenetics at clinical level. This idea was shared 
by stakeholders who gave credit to the potential socio-economic impact of 
this line of research and funded new projects that are going to extend the 
studies included in this dissertation (“Fondazione Umberto Veronesi” and 
European Union (Marie SkŁodowska-Curie fellowship)). Moving the focus 
of analysis from individual variants to pathways was another key point in 
chapters 3-7 of this dissertation and it is also the main methodological 
frame guiding the genetic analysis of the new projects. One important 
advance of the new analyses will be the computing of polygenic scores at 
both common and rare variant level, and their calculation using all available 
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variants in the genome/exome but also variants in specific pathways only. 
Indeed part of the so-called missing heritability may be due to the effect of 
rare (and possibly unknown) variants, as suggested in chapter 4.  
Ideally, prediction algorithms should include comprehensive genetic 
information (common and rare variants), but also clinical-demographic 
variables, a point that will be addressed in ongoing projects. Indeed the 
combination of these predictors is expected to fit the hypothesized 
mechanisms underling TRD and maximize the chances to develop valid and 
reproducible tests suitable for clinical application.  
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